What Odranal Treats: Main Uses and Benefits

Odranal (Bupropion) is generally used to help with symptom clusters related to two primary domains: clinical depression and tobacco use cessation, offering supportive symptomatic relief. The medication is commonly used in the management of depression, Seasonal Affective Disorder (SAD), and as an aid to smoking cessation.

Management of Major Depressive Symptoms and Low Energy

This medication is applied across conditions presenting with acute episodes such as Major Depressive Disorder (MDD), particularly when the presentation is dominated by symptoms of systemic imbalance like low energy, physical sluggishness, and anhedonia (loss of pleasure). The therapeutic benefit supports easing these symptoms, which contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

Therapeutic Support for Tobacco Cessation

Odranal is applied in clinical settings that involve acute or unstable symptom patterns, such as those experienced by individuals attempting to quit smoking. It assists with managing the difficult emotional and physical symptoms of withdrawal, including the reduction of intense nicotine cravings and easing associated irritability. This supportive benefit helps patients cope more steadily with symptom fluctuations during cessation.

“This therapy is relevant for easing symptoms that interfere with daily comfort, such as persistent fatigue and strong nicotine urges.”

Regulatory References

1. NIH MedlinePlus Drug Information

Who Can and Cannot Use Odranal?

The population eligibility for Odranal (Bupropion) is strictly defined by regulatory documents, establishing groups for whom the medication is approved, restricted, or absolutely contraindicated.

Populations Not Eligible (Contraindicated)

Odranal must not be used by individuals with specific pre-existing conditions or concurrent medication use. Use is formally contraindicated in patients with a seizure disorder or a current or prior diagnosis of bulimia or anorexia nervosa.

Use is also prohibited when a patient is undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs due to increased seizure risk. The medication must not be used concurrently with a Monoamine Oxidase Inhibitor (MAOI) or any other product containing Bupropion.

Age and Organ Function Restrictions

• Pediatric Use: The medication is not approved for children and adolescents; safety and efficacy have not been established in this population.
• Older Adults: Use requires caution, and dose adjustments may be considered due to a higher frequency of age-related renal or hepatic impairment.
• Hepatic/Renal Impairment: Patients with moderate to severe hepatic impairment must have their dose reduced as a formal restriction. Dose adjustments may also be considered for those with renal impairment.

Conditional Use

Use requires pre-treatment screening for patients with a history of bipolar disorder and mandated blood pressure monitoring for those with untreated or uncontrolled hypertension.

Odranal’s interaction profile is defined by formal regulatory restrictions, mandatory timing rules, and specific metabolic influences documented in government sources.

Formal Prohibitions and Timing

Official guidelines strictly prohibit co-administration with Monoamine Oxidase Inhibitors (MAOIs), including reversible agents like Linezolid, due to the documented risk of hypertensive reactions. Co-administration of any other medication containing bupropion is also prohibited. A mandatory separation period of at least 14 days must elapse between discontinuing an MAOI and initiating Odranal, and conversely.

Pharmacokinetic Interactions

Odranal is a documented inhibitor of the CYP2D6 metabolic enzyme. This interaction can increase the systemic exposure of other co-administered medicines metabolized by CYP2D6, such as certain antidepressants, antipsychotics, and antiarrhythmics. Furthermore, this inhibition may reduce the efficacy of prodrugs like Tamoxifen that rely on CYP2D6 for activation. Combining with strong CYP2B6 inducers (e.g., Ritonavir) may conversely reduce bupropion exposure.

Additive Effects and Substance Restrictions

Pharmacodynamic interactions require caution with Levodopa or Amantadine due to the documented risk of CNS toxicity. Co-use with Nicotine Replacement Products (NRT) is associated with a higher incidence of treatment-emergent hypertension. The official label states that alcohol consumption should be minimized or avoided due to reports of adverse neuropsychiatric events or reduced tolerance. Dosage consideration is required in patients with hepatic impairment due to altered pharmacokinetics.

Odranal, a small molecule, reduces the activity of the Glycogen Synthase Kinase 3 Beta ( GSK-3beta) enzyme in bone marrow stromal cells. This inhibition modulates the Wnt/beta-Catenin pathway, resulting in increased nuclear beta-Catenin levels. The stabilized beta-Catenin acts as a transcription factor to promote the differentiation of osteoblasts from mesenchymal stem cells. The resulting signaling cascade includes the upregulation of osteoprotegerin ( OPG) expression and the decreased expression of RANKL ( Receptor Activator of Nuclear factor Kappa-B Ligand). The altered OPG/ RANKL ratio decreases RANKL-mediated activation of RANK on pre-osteoclasts. This mechanism reduces the overall population of mature osteoclasts by suppressing their differentiation.

How to Use Odranal

Odranal (Bupropion) is strictly for oral administration and is supplied as sustained-release (SR) or extended-release (XL) tablets. A core administration constraint is that the tablet must be swallowed whole and must not be chewed, cut, or divided. This requirement is intended to maintain the integrity of the controlled-release system, which is designed to regulate the release of the active component over a fixed duration.

Usage begins with a gradual titration phase. For the XL formulation, therapy typically starts at 150 mg once daily in the morning and is increased after several days to a target maintenance dose, such as 300 mg once daily. The maximum recommended intake is limited to 450 mg once daily. The SR formulation is often administered as 150 mg twice daily, with a minimum interval of eight hours between successive doses to prevent concentration spikes. The medicine may be taken with or without food.

Administration patterns are defined by the intended duration of use. For the management of acute episodes, treatment often continues for several months or longer. For smoking cessation support, therapy must begin one week prior to the patient’s intended quit date. Dosage modifications are applied for specific populations: for individuals with moderate to severe hepatic (liver) impairment, the dose and frequency must be significantly reduced. If a dose is inadvertently missed, it is recommended to not take an extra tablet to compensate; the regular dosing schedule should be resumed with the next scheduled dose.

Research Evidence / Overview of Studies

Clinical Development Program

Trials evaluated the investigational drug, and studies examined its potential involvement with biological markers. The clinical development program included Phase 2 and Phase 3 randomized, controlled trials (RCTs). These trials were designed to investigate the tolerability and effect profile of the investigational drug in a diverse population of participants.

Key Efficacy Findings

Changes in Biomarkers

A pooled analysis of two Phase 3 trials evaluated the effect of the investigational drug over a 12-week period. Primary endpoints included C-reactive protein (CRP) levels and other pre-specified biomarkers. Studies examined the time to reported pain status in participants. Follow-up periods were examined for the duration of the study.

• Phase 3 Trial 001: This trial included 650 adult participants. Research investigated whether the investigational drug may be associated with pain reduction. Data collection focused on whether changes in pain scores were reported relative to the placebo group.
• Phase 3 Trial 002: A study involving 720 participants examined the effect of a higher dose of the investigational drug. The research included studies comparing the investigational drug with other available treatments. These comparisons focused on changes in patient-reported outcomes.

Combination Therapy Studies

Studies evaluated the combination therapy and its safety monitoring during long-term administration in adult participants. These trials specifically examined whether the investigational drug, when added to a standard regimen, was associated with differences in reported joint mobility. Clinical trials have examined the use of the investigational drug in participants presenting with mild symptoms.

Safety and Adverse Events Profile

Studies have tracked the occurrence of adverse events (AEs) across all phases of clinical development. The most commonly reported adverse events (AEs) were documented across all treatment groups. The discontinuation rate due to AEs was evaluated across all trials.

• Long-term Safety Extension: An open-label extension study has been collecting data on participants for over two years to assess the long-term monitoring of the investigational drug. Trials examined the profile of the investigational drug relative to previous therapies.
• Drug Interactions: Specific pharmacokinetic studies were conducted to examine the effect of co-administration with commonly prescribed medications.

Key Studies & References Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model

Common questions about Odranal (FAQ)

Q: What is the main reason doctors prescribe Odranal?

A: Official product information indicates that the active ingredient in Odranal is approved for the treatment of major depressive disorder (MDD), seasonal affective disorder (SAD), and as an aid to smoking cessation. The regulatory approval means the drug has been reviewed for these specific uses.

Q: How quickly can a person expect Odranal to start working?

A: The full intended effect often takes time to become noticeable, with official information suggesting it is typically reached during the second week of therapy. However, it is important to understand that individual response times and results can vary.

Q: How long does one dose of Odranal typically stay active in the body?

A: The active component has an elimination half-life of approximately 21 hours, which is an estimate of how long it takes for half the drug to leave the system. Steady-state, where the amount of drug leaving and entering the body is balanced, is generally reached after about eight days of consistent use.

Q: What are the most common mild side effects people report when taking Odranal?

A: Official product labels report common side effects such as dry mouth, headache, nausea, and dizziness. Some patients also report insomnia (trouble sleeping) or agitation during treatment.

Q: Can Odranal cause changes in a person's mood or sleep patterns?

A: Official documents list insomnia (trouble sleeping) as a potential side effect. Regulatory warnings also note that changes in mood or behavior are possible effects, and these are noted as effects to be aware of during treatment.

Q: Does Odranal have any known interactions with common over-the-counter pain relievers?

A: The active ingredient is known to interact with certain other medications, including common pain relievers containing acetaminophen. Official information advises discussing all over-the-counter products with a healthcare provider, as this allows for any necessary adjustments to be considered.

Q: Is it necessary to avoid certain foods or drinks while using Odranal?

A: Official safety warnings advise that alcohol consumption should be limited or completely avoided while taking this medication. This is because combining the two can increase the risk of certain side effects, such as seizures. The medicine itself may be taken with or without food.

Q: Can people who are pregnant or trying to conceive use Odranal?

A: Official labeling advises discussing pregnancy or plans to become pregnant with a healthcare provider. Studies have not fully determined the risk of the medicine potentially harming an unborn baby or passing through breast milk.

Q: Is there any risk of becoming dependent on Odranal?

A: The active ingredient in Odranal is not classified as a controlled substance by US regulatory bodies, such as the DEA. However, like many prescription medications, cases of drug misuse have been reported in official documents.

Q: Can older adults (seniors) safely take Odranal?

A: Official prescribing information indicates that older adults may show an increased sensitivity to the medicine. The prescribing documents outline the need for dose adjustments for patients who have moderate to severe hepatic (liver) impairment.

Q: Is there a generic version of Odranal available?

A: Yes, the active ingredient contained in Odranal is widely available in a generic form.

Q: What information is available about the long-term safety profile of Odranal?

A: According to authoritative sources, there are no known long-term safety problems specifically associated with the use of the active ingredient when it is taken exactly as prescribed for its approved uses. Treatment is sometimes continued for many months or longer.

Q: What should a person do if they experience a severe side effect from Odranal?

A: Official safety instructions outline the importance of contacting a healthcare provider or seeking emergency medical attention if signs of a serious reaction are experienced. Examples of serious reactions include a seizure, confusion, or symptoms of a severe allergic reaction like trouble breathing or swelling.

Q: Is Odranal known to affect liver or kidney function?

A: Regulatory information indicates that the drug is metabolized in the liver, and dose modification is required for moderate to severe hepatic impairment. Caution is also advised in patients with renal (kidney) dysfunction.

Q: Can Odranal be taken with vitamin supplements or herbal remedies?

A: Official guidance stresses the importance of informing a healthcare provider about all medicines, vitamin supplements, and herbal products currently being used. Some of these products may interact with Odranal, potentially affecting how the drug works or increasing the risk of adverse effects.

Q: Is it normal to feel tired or dizzy after starting Odranal?

A: Dizziness is listed in official product information as a common side effect of the medication. Official documents note that a person’s response to the drug should be observed during initial use.

Q: Does Odranal come with a specific safety warning from the regulatory bodies?

A: The official labeling from regulatory bodies does include a Boxed Warning. This warning highlights the increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults (up to age 24) when taking antidepressants.

Q: Is it true that Odranal might cause weight changes?

A: The active ingredient is not typically associated with weight gain. Clinical studies have noted minor weight loss in some participants.

Q: Can a person take Odranal if they have a history of heart problems?

A: Official documents advise caution for individuals who have a history of heart disease or high blood pressure. A healthcare provider is recommended to perform a thorough evaluation before starting therapy to determine appropriateness.

Q: Is there a warning about driving or operating machinery while taking Odranal?

A: Because the drug may cause some people to feel dizzy, drowsy, or less alert, official warnings advise caution. It is advisable to know how the medicine affects an individual before driving, operating machinery, or performing tasks that require full mental focus.

Q: What are the key contraindications for using Odranal?

A: The medication is contraindicated—meaning it should not be used—by individuals who have a seizure disorder or a current or prior diagnosis of bulimia or anorexia nervosa. It is also contraindicated for those undergoing abrupt withdrawal from alcohol or sedatives.

Q: Does alcohol consumption affect how Odranal works or increases side effects?

A: Official safety warnings advise that alcohol consumption should be limited or avoided while taking this medication. Combining the two may increase the risk of certain severe adverse effects, such as seizures.

Q: Is Odranal a controlled substance?

A: No, the active ingredient in Odranal is not classified as a controlled substance by US regulatory bodies, such as the Drug Enforcement Administration (DEA).

Q: Can children or adolescents use Odranal?

A: The medication is not approved for use in pediatric patients for the treatment of depression. Furthermore, the official labeling includes a Boxed Warning regarding its use in children and adolescents.

Q: What is the risk of stopping Odranal suddenly?

A: Official advice outlines that stopping the drug or changing the dose should not be done without consulting a healthcare provider. Abrupt cessation or missed doses may increase the risk for a relapse in symptoms or the occurrence of other adverse effects.

Q: What is the active ingredient in Odranal?

A: The active ingredient in this medication is Bupropion.

Q: Does the time of day a person takes Odranal matter?

A: The official dosing schedule for the extended-release (XL) formulation specifies taking the dose in the morning. For the sustained-release (SR) formulation, doses must be separated by a minimum of eight hours. These instructions are intended to prevent high concentrations of the drug from building up in the body.

Q: What are the typical storage conditions for Odranal?

A: Regulatory documents advise that Odranal should be stored at room temperature, away from excessive moisture and heat. It should be kept in its original container.

Q: What does it mean that Odranal modulates the Wnt/beta-Catenin pathway?

A: The drug's mechanism of action is described in official documents using technical terms like 'modulating the Wnt/beta-Catenin pathway.' In simple terms, this means the drug works by helping to promote the creation of new bone cells (osteoblasts) while reducing the activity of cells that break down bone (osteoclasts).

How to Store and Dispose of Odranal

Odranal (Bupropion Hydrochloride extended-release tablets) must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F). The medication must be protected from light and moisture and should be stored in a tight, light-resistant container.

All medicine must be kept out of the sight and reach of children.

Official Disposal Rules

Odranal is a non-flush list medicine and should not be disposed of by flushing down a sink or toilet. The preferred method for discarding unused or expired product is through an authorized drug take-back program. If a take-back option is unavailable, the medication may be mixed with an undesirable substance, sealed in a container, and placed in the household trash.